Feedback
Settings

Settings

Goto Application

1. WO2021019249 - CLOZAPINE FOR USE IN TREATING PATHOGENIC IMMUNOGLOBULIN DRIVEN B CELL DISEASE

Submit observation
PermaLink
Publication Number WO/2021/019249
Publication Date 04.02.2021
International Application No. PCT/GB2020/051835
International Filing Date 30.07.2020
IPC
A61K 31/5513 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
55having seven-membered rings, e.g. azelastine, pentylenetetrazole
551having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
55131,4-Benzodiazepines, e.g. diazepam
A61K 45/06 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/60 2017.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
56the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
59obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
60the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61P 37/06 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
02Immunomodulators
06Immunosuppressants, e.g. drugs for graft rejection
A61P 37/08 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
08Antiallergic agents
CPC
A61K 31/5513
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
55having seven-membered rings, e.g. azelastine, pentylenetetrazole
551having two nitrogen atoms, e.g. dilazep
55131,4-Benzodiazepines, e.g. diazepam ; or clozapine
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 37/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
02Immunomodulators
06Immunosuppressants, e.g. drugs for graft rejection
A61P 37/08
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
08Antiallergic agents
Applicants
  • ZARODEX THERAPEUTICS LIMITED [GB]/[GB]
Inventors
  • JOLLES, Stephen
  • ASHRAFIAN, Houman
  • MCHALE, Duncan
Agents
  • AYLETT, Sophie-Beth
Priority Data
1910873.730.07.2019GB
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) CLOZAPINE FOR USE IN TREATING PATHOGENIC IMMUNOGLOBULIN DRIVEN B CELL DISEASE
(FR) CLOZAPINE DESTINÉE À ÊTRE UTILISÉE DANS LE TRAITEMENT D'UNE MALADIE DES LYMPHOCYTES B ENTRAÎNÉE PAR DES IMMUNOGLOBULINES PATHOGÈNES
Abstract
(EN)
This invention relates to the compound clozapine and its major metabolite norclozapine, pegylated derivatives thereof and prodrugs thereof and pharmaceutically acceptable salts and solvates thereof for use in the treatment or prevention of a pathogenic immunoglobulin driven B cell disease, a pathogenic immunoglobulin driven B cell disease with a T cell component or a pathogenic IgE driven B cell disease. The invention also provides pharmaceutical compositions containing such compounds.
(FR)
La présente invention concerne le composé clozapine et son métabolite majeur, la norclozapine, des dérivés pegylés de ceux-ci et des promédicaments de ceux-ci et des sels et des solvates pharmaceutiquement acceptables de ceux-ci destinés à être utilisés dans le traitement ou la prévention d'une maladie des lymphocytes B entraînée par une immunoglobuline pathogène, une maladie des lymphocytes B entraînée par une immunoglobuline pathogène avec un composant de lymphocyte T ou une maladie des lymphocytes B entraînés par des IgE pathogènes. L'invention concerne également des compositions pharmaceutiques contenant de tels composés.
Latest bibliographic data on file with the International Bureau
# -